Medical Technology

As a spinoff from UT Austin, ARTS Surgical Inc. is pioneering a new era in orthopedic and neurosurgical procedures with our state-of-the-art steerable drilling robotic system. Our mission is to revolutionize minimally invasive surgeries by enhancing precision, safety, and efficiency in diagnosing and treating conditions involving complex hard tissue anatomies. A key limitation of current surgical tools lies in their rigidity, which restricts access to straight-line trajectories and prevents clinicians from reaching deep, intricate anatomical regions.

RNA technology thus has the potential to revolutionize medicine with life-saving and even curative treatments for previously unmet clinical needs, including cancers, autoimmune disorders, and neurodegenerative diseases. The primary bottleneck in the translation of the 1300+ early-stage RNA programs in existence has been the biological delivery system, not the RNA drug payload itself, due to toxicity, immunogenicity, and the inability to target specific cells, tissues, and organs, leading to off-target effects.

Currently hemophilia A patients must either infuse Factor VIII (FVIII) clotting factor 2-3 times per week or take weekly injections.  30% of hemophilia A patients develop inhibitors (neutralizing antibodies) to their missing clotting factor. FVIII gene therapies that were in development or Roctavian, which was recently approved are not durable, meaning they fail to deliver the promised single infusion treatment for hemophilia.  Worse still, patients with inhibitors were ineligible for these gene therapies.

Current drug discovery is inefficient, slow, and costly; only a transformative approach to de-risk and economize discovery will deliver novel cancer therapeutics to suffering patients. To this end, Empath Biosciences has developed a process which will lead to a three-fold increase in optimized leads, each with >50% improvement in the probability of technical and regulatory success (PTRS) over standard small-molecule based discovery.

Parasight System Inc. aims to address the inefficiencies and inaccuracies in traditional veterinary diagnostic methods. Current approaches to fecal exams, heartworm detection, and Lyme disease testing often rely on manual processes that are time-consuming, prone to error, and dependent on subjective interpretation. This can lead to missed diagnoses or delayed treatments, ultimately affecting the health and well-being of animals. Parasight System's solution leverages advanced AI technology and antigen-based fluorescence detection to automate and enhance diagnostic accuracy.